GRCE Stock — Grace Therapeutics Inc.: Cash, EV, Pipeline

Share price

$2.11

Market cap

$44.4M

Cash

$13.8M

Enterprise value

$30.6M

Balance sheet

Cash	$13.8M
Debt	$0.0M
Net cash	$13.8M
Enterprise value	$30.6M
Basic shares	16.3M shares
Fully diluted shares	27.7M shares
Fully diluted market cap	$58.5M
Cash per share	$0.84

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading GRCE daily closes…

Loading price history…

Pipeline assets

GTx-104

Phase 3 · Active Modality: injectable formulation

Indications

aneurysmal subarachnoid hemorrhage (aSAH) (Phase 3)

Status note Injectable nimodipine formulation for improved management of hypotension in hospitalized aSAH patients. Pivotal Phase 3 STRIVE-ON randomized safety trial vs nimodipine oral capsules completed enrollment September 2024; NDA submitted to FDA under 505(b)(2); FDA issued a Complete Response Letter and the company is addressing CRL items toward NDA resubmission.

GTx-101

Stage not disclosed · Terminated

Indications

postherpetic neuralgia (PHN) (Stage not disclosed)

Status note Discontinued June 2026 per strategic decision to focus on GTx-104; company impaired the capitalized IPR&D carrying value of GTx-101 and GTx-102 ($13.533M combined). Company notes it may seek to maximize value via licensing or sale.

GTx-102

Stage not disclosed · Terminated

Indications

Ataxia Telangiectasia (Stage not disclosed)

Status note Discontinued June 2026 per strategic decision to focus on GTx-104; company impaired the capitalized IPR&D carrying value of GTx-101 and GTx-102 ($13.533M combined). Company notes it may seek to maximize value via licensing or sale.

Per-asset detail extracted from the 10-Q filed 2026-08-13. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	GTX-104
Lead indication	Aneurysmal Subarachnoid Hemorrhage (aSAH)
Lead phase	Phase 3
Active trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05995405	Phase 3	Active, not recruiting	Sponsor	GRCE	—	Aneurysmal Subarachnoid Hemorrhage (aSAH)	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 1 active trials for Grace Therapeutics Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

GRCE — Grace Therapeutics Inc.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials